NIH R01 · 2025
Pharmacogenomics of an ovulation modulator and the impact on delay of ovulation
SUMMARY The proposed project aims to increase our knowledge regarding the intersection of pharmacogenomics and drug therapeutics. A commonly used ovulation modulator, ulipristal acetate (UPA), works by blocking progesterone action in the preovulatory follicle and is metabolized through the cytochrome P450 pathway. We have demonstrated that UPA is converted to inactive metabolites by the enzyme cytochrome P450 3A5 (CYP3A5). Moreover, we established that the NHP ovarian follicle, the site of UPA action as an EC, expresses remarkably high levels of CYP3A5 through the periovulatory interval and luteal development which may further impact the therapeutic effect of this drug. Because active…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.